Neoadjuvant treatment for gastric cancer

Journal of Gastric Cancer

Volumn 13, Issue 2, 2013, Pages 73-78

  Schuhmacher, Christoph ^a,c   Reim, Daniel ^a,b   Novotny, Alexander ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b National Cancer Center   (South Korea)

^c Diakonie Klinikum Stuttgart   (Germany)

Author keywords

Chemoradiotherapy; Chemotherapy; Gastric cancer; Neoadjuvant therapy; Surgery

Indexed keywords

CISPLATIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID;

ADJUVANT CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; ENDOSCOPIC ECHOGRAPHY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGOGASTRODUODENOSCOPY; GASTRECTOMY; HUMAN; LAPAROSCOPY; LYMPH NODE DISSECTION; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); POSTOPERATIVE COMPLICATION; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STOMACH CANCER; UNSPECIFIED SIDE EFFECT;

EID: 84879458232     PISSN: 2093582X     EISSN: 20935641     Source Type: Journal    
DOI: 10.5230/jgc.2013.13.2.73     Document Type: Review

References (29)

1. Meyer HJ, Hölscher AH, Lordick F, Messmann H, Mönig S, Schumacher C, et al. Current S3 guidelines on surgical treat-ment of gastric carcinoma. Chirurg 2012;83:31-37.
2. Agboola O. Adjuvant treatment in gastric cancer. Cancer Treat Rev 1994;20:217-240.
3. Middleton G, Cunningham D. Current options in the manage-ment of gastrointestinal cancer. Ann Oncol 1995;6 Suppl 1:17-25.
4. Wilke H, Preusser P, Fink U, Gunzer U, Meyer HJ, Meyer J, et al. Preoperative chemotherapy in locally advanced and nonre-sectable gastric cancer: a phase II study with etoposide, doxo-rubicin, and cisplatin. J Clin Oncol 1989;7:1318-1326.
5. D'Ugo D, Rausei S, Biondi A, Persiani R. Preoperative treat-ment and surgery in gastric cancer: friends or foes? Lancet Oncol 2009;10:191-195.
6. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20.
7. Ychou M, Boige V, Pignon JP, Conroy T, Bouché O, Lebreton G, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011;29:1715-1721.
8. Schuhmacher C, Gretschel S, Lordick F, Reichardt P, Hohen-berger W, Eisenberger CF, et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol 2010;28:5210-5218.
9. Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009;27:851-856.
10. van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, et al; CROSS Group. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012;366:2074-2084.
11. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A; ACTS-GC Group. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357:1810-1820.
12. Sasako M, Kinoshita T, Furukawa H, Yamaguchi T, Nashimoto A, Fujii M, et al. Five-year results of the randomized phase III trial comparing S-1 monotherapy versus surgery alone for stage II/III gastric cancer patients after curative D2 gastrec-tomy (ACTS-GC study). Ann Oncol 2010;21:viii225-249.
13. Ott K, Lordick F, Blank S, Büchler M. Gastric cancer: surgery in 2011. Langenbecks Arch Surg 2011;396:743-758.
14. Feussner H, Omote K, Fink U, Walker SJ, Siewert JR. Prethera-peutic laparoscopic staging in advanced gastric carcinoma. Endoscopy 1999;31:342-347.
15. Li H, Zhu F, Cao Y, Zhai L, Lin T. Meta-analyses of random-ized trials assessing the effect of neoadjuvant chemotherapy in locally advanced gastric cancer. J Clin Oncol (Meeting Ab-stracts) 2010;28:4042.
16. Ronellenfitsch U, Schwarzbach M, Hofheinz R, Kienle P, Ho-henberger P, Jensen K, et al; GE Adenocarcinoma Meta-analy-sis Group. Meta-analysis of preoperative chemotherapy (CTX) versus primary surgery for locoregionally advanced adenocar-cinoma of the stomach, gastroesophageal junction, and lower esophagus (GE adenocarcinoma). J Clin Oncol 2010;28:15s.
17. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al; Upper Gastrointestinal Clinical Studies Group of theNational Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358:36-46.
18. Fiorica F, Cartei F, Enea M, Licata A, Cabibbo G, Carau B, et al. The impact of radiotherapy on survival in resectable gastric carcinoma: a meta-analysis of literature data. Cancer Treat Rev 2007;33:729-740.
19. Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J; Australasian Gastro-Intestinal Trials Group. Survival ben-efits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007;8:226-234.
20. Urschel JD, Vasan H. A meta-analysis of randomized con-trolled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2003;185:538-543.
21. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stom-ach or gastroesophageal junction. N Engl J Med 2001;345:725-730.
22. Botterweck AA, Schouten LJ, Volovics A, Dorant E, van Den Brandt PA. Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol 2000;29:645-654.
23. Powell J, McConkey CC. The rising trend in oesophageal ade-nocarcinoma and gastric cardia. Eur J Cancer Prev 1992;1:265-269.
24. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr. Rising inci-dence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991;265:1287-1289.
25. Okabayashi T, Gotoda T, Kondo H, Inui T, Ono H, Saito D, et al. Early carcinoma of the gastric cardia in Japan: is it different from that in the West? Cancer 2000;89:2555-2559.
26. Chung JW, Lee GH, Choi KS, Kim DH, Jung KW, Song HJ, et al. Unchanging trend of esophagogastric junction adenocar-cinoma in Korea: experience at a single institution based on Siewert's classification. Dis Esophagus 2009;22:676-681.
27. Reim D, Gertler R, Novotny A, Becker K, zum Büschenfelde CM, Ebert M, et al. Adenocarcinomas of the esophagogastric junction are more likely to respond to preoperative chemother-apy than distal gastric cancer. Ann Surg Oncol 2012;19:2108-2118.
28. Ajani JA, Faust J, Ikeda K, Yao JC, Anbe H, Carr KL, et al. Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol 2005;23:6957-6965.
29. Messager M, Lefevre JH, Pichot-Delahaye V, Souadka A, Pies-sen G, Mariette C; FREGAT working group-FRENCH. The impact of perioperative chemotherapy on survival in patients with gastric signet ring cell adenocarcinoma: a multicenter comparative study. Ann Surg 2011;254:684-693.